Evaxion Biotech A/S Q1 FY2026 earnings call

1. Key focus areas include business development and partnering, R&D focus with progress in EVX01 Phase 2 study, AI Immunology Platform in R&D, and maintaining disciplined resource allocation. 2. Organization reorganized with Begida promoted to CSO and COO, Jens Bishnorheve added to board. 3. R&D highlights include EVX01 Phase 2 biomarker and T cell immune data showing 86% immunogenicity conversion rate, data on AI immunology platform in glioblastoma, and work on polio vaccine concept. 4. Financials in Q1 2026 show net loss of 3.6 million US, cash position at 18.4 million with cash runway until second half of 2027.

1. Expect to announce three-year data including clinical outcome for EVX01 in second half of 2026. 2. Evaluate and discuss additional cancer indications with further trials in partnerships. 3. Cash runway remains unchanged into the second half of 2027 with no assumption of partnerships or deals within that time frame until communicated.

Q: Regarding three-year EVX01 data, when will it be updated and in what context?

A: Will be updated in the context of a scientific meeting, not outside of that.

Q: For GBM data, is it strategic intent to take into humans or seek partnership?

A: Excited about the data, anticipate it will be a partnering approach.

Q: About expansion and design philosophy in cancer, how is the approach to targets?

A: Look at multiple antigen sources, consider medical need and treatment landscapes.

Q: About designing new vaccines, use one personal vaccine for multiple tumor types or individual for each?

A: Depends on patient omics data and profiles, for conserved antigens develop off-the-shelf vaccine.

Q: About partnerships, detail on broad platform licensing or specific asset-based collaboration?

A: Can't provide details yet but pushing forward strategically to maximize value.

Q: About autoimmune platform part, when will more details be available?

A: Current plan is to report in second half aligned to scientific relevant conferences.